
Abselion appoints Dale Gordon as Chair
Lucy Batizovsky | March 30, 2026 | Appointment | | Abselion
Abselion has appointed Dale Gordon as Chair of the Board of Directors.
Bringing over 30 years of experience to the role, Gordon plans to support the sustainable growth and long-term value creation across multiple parts of the company.
Most recently he served as CEO of Mirus Bio, where he led the growth and development of the company. His other previous roles include CEO at Gemini Bi and multiple senior leadership positions at GE Life Sciences (now Cytiva), and Merck Millipore.
Ruizhi Wang, CEO and Founder of Abselion, said: “Dale joins us at a point where the company is moving from early momentum into a more execution-focused phase, with growing commercial engagement and increasing international activity.
“His experience in guiding life sciences companies through this transition will be an invaluable asset as we continue our global expansion.”
Dale Gordon, Chair of the Board of Directors, Abselion, said: “I’m looking forward to working with the Board to support the company’s continued growth, strengthen its commercial direction, and help guide the next phase of its journey.”
Gordon succeeds Simon Douglas, who is stepping down after more than four years in the role.
Related Content

Abselion establishes a US subsidiary in Massachusetts
Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. …






